强生(JNJ.US)first-in-class新药在国内申报上市 CDE将其纳入拟优先审评

智通财经11-20

智通财经APP获悉，11月19日，CDE官网显示，强生(JNJ.US)1类新药盐酸伊可白滞素片申报上市，适用于治疗适合接受系统性治疗或光疗的中重度斑块状银屑病成人患者和年满12岁的儿童患者。同日，盐酸伊可白滞素片也被 CDE 纳入了拟优先审评，标志其在中国上市进程迈出关键一步。盐酸伊可白滞素片(Icotrokinra)是强生斥资近10亿美元从 Protagonist 引进的 first-in-...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2584347681?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-20 21:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584347681","market":"hk","top_or_hot":-1,"title":"强生(JNJ.US)first-in-class新药在国内申报上市 CDE将其纳入拟优先审评","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，11月19日，CDE官网显示，强生(JNJ.US)1类新药盐酸伊可白滞素片申报上市，适用于治疗适合接受系统性治疗或光疗的中重度斑块状银屑病成人患者和年满12岁的儿童患者。同日，盐酸伊可白滞素片也被 CDE 纳入了拟优先审评，标志其在中国上市进程迈出关键一步。盐酸伊可白滞素片(Icotrokinra)是强生斥资近10亿美元从 Protagonist 引进的 first-in-...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1371794.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>强生(JNJ.US)first-in-class新药在国内申报上市 CDE将其纳入拟优先审评</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n强生(JNJ.US)first-in-class新药在国内申报上市 CDE将其纳入拟优先审评\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-20 21:22 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1371794.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，11月19日，CDE官网显示，强生(JNJ.US)1类新药盐酸伊可白滞素片申报上市，适用于治疗适合接受系统性治疗或光疗的中重度斑块状银屑病成人患者和年满12岁的儿童患者。同日，盐酸伊可白滞素片也被 CDE 纳入了拟优先审评，标志其在中国上市进程迈出关键一步。盐酸伊可白滞素片(Icotrokinra)是强生斥资近10亿美元从 Protagonist 引进的 first-in-...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1371794.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2471134952.CNY","symbol_name":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1371794.html","article_id":"2584347681","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584347681","pubTimestamp":1763644954,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"同日，盐酸伊可白滞素片也被 CDE 纳入了拟优先审评，标志其在中国上市进程迈出关键一步。盐酸伊可白滞素片是强生斥资近10亿美元从 Protagonist 引进的 first-in-class 口服多肽药物。今年7月该药在美国申报上市，9月在欧洲申报上市。截至第 24 周，Icotrokinra 的 AE 发生率在数值上低于氘可来昔替尼。据悉，盐酸伊可白滞素片由强生与Protagonist Therapeutics公司联合开发。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","JNJ":"强生","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","CDE":"科尔黛伦矿业","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","BK4017":"黄金","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU2592432038.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"A\" (USD) ACC","LU2430703095.HKD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (HKD) INC","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU2430703178.SGD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (SGDHDG) INC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4559":"巴菲特持仓","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU2430703251.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (USD) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","BK4588":"碎股","BK4550":"红杉资本持仓","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU2505996681.GBP":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (GBPHDG) INC","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","LU1223082519.USD":"SCHRODER ISF GLOBAL GOLD \"A\" (USD) INC AV","LU2505996509.AUD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (AUDHDG) INC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","SG9999002232.USD":"Allianz Global High Payout USD","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","SG9999002224.SGD":"Allianz Global High Payout SGD","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC"},"translate_title":"Johnson & Johnson (JNJ.US) first-in-class new drug declared for marketing in China CDE included it in the proposed priority review","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":1.5,"CDE":1.5},"content_text":"智通财经APP获悉，11月19日，CDE官网显示，强生(JNJ.US)1类新药盐酸伊可白滞素片申报上市，适用于治疗适合接受系统性治疗或光疗的中重度斑块状银屑病成人患者和年满12岁的儿童患者。同日，盐酸伊可白滞素片也被 CDE 纳入了拟优先审评，标志其在中国上市进程迈出关键一步。盐酸伊可白滞素片(Icotrokinra)是强生斥资近10亿美元从 Protagonist 引进的 first-in-class 口服多肽药物(IL-23R 拮抗剂)。今年7月该药在美国申报上市，9月在欧洲申报上市。值得一提的是，Icotrokinra 是当前全球首个也是唯一一个报上市的 IL-23R 靶向药物。强生对此寄予厚望，预计年峰值销售额有望达到50亿美元以上。此前该药在美国和欧盟的上市申请包含四项关键性 III 期研究的数据，包括 ICONIC-LEAD、ICONIC-TOTAL 以及 ICONIC-ADVANCE 1 和 ICONIC-ADVANCE 2。ICONIC-ADVANCE1和2为随机对照 III 期临床试验，旨在评估 Icotrokinra 与氘可来昔替尼(全球首个获批的 TYK-2 变构抑制剂)和安慰剂相比，在中重度斑块状银屑病患者中的疗效和安全性。共同主要终点是受试者达到 PASI 90 (银屑病面积与严重程度指数改善 90%)和 IGA 评分为 0/1(皮肤症状消除或几乎消除)，且至少改善2级。在这两项研究中， Icotrokinra与安慰剂相比，在第16周达到了两个共同主要终点，不良事件发生率相似 ，并且在时间点显示出优于氘可来昔替尼的疗效和安全性。与安慰剂(第16周)和 氘可来昔替尼(第16周和第24周)相比，Icotrokinra 显示出更优异的皮肤清除率。Icotrokinra 的不良事件 (AE) 发生率与安慰剂相似，未发现新的安全信号。截至第 24 周，Icotrokinra 的 AE 发生率在数值上低于氘可来昔替尼。在所有研究中，汇总安全性数据显示，Icotrokinra 组 (49.1%) 和安慰剂组 (51.9%) 之间经历不良事件 (AE) 的患者比例相似，未发现新的安全信号。此外，强生还启动了 III 期 ICONIC-ASCEND研究，这是首个旨在证明口服药 Icotrokinra 优于注射生物制剂乌司奴单抗的头对头研究。长期数据方面，ICONIC-LEAD 研究中，Icotrokinra 在第 52 周时表现出对成人和青少年患者持续的皮肤清除率和良好的安全性。据悉，盐酸伊可白滞素片由强生与Protagonist Therapeutics公司联合开发。根据双方合作协议，强生公司自Icotrokinra进入II期临床试验阶段起，便获得了该药物在全球范围内的独家开发及商业化权利。此次CDE拟纳入优先审评的决定，主要基于该药物在多项国际多中心临床试验中展现的卓越疗效和良好安全性特征，其临床数据为中重度银屑病患者，特别是儿科患者人群，提供了有力的循证医学证据。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584347681","isCrawlerRequest":true}